TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Wave Neuroscience says its FDA-cleared, EEG-guided magnetic stimulation system produced a 52% reduction in PTSD symptoms and remission in 68% of clinical-trial participants. The company has not yet publicly released the full findings, so the reported results cannot be fully assessed or directly compared with other treatments.
Wave Neuroscience says its FDA-cleared, personalized magnetic stimulation system for post-traumatic stress disorder produced remission in 68% of clinical-trial participants and reduced symptoms by 52%. The company has not yet released the full trial findings, leaving details needed to judge the result—including the study design and how remission was defined—unclear.
The system, developed by the California-based company with researchers at the Texas A&M Health Institute of Biosciences and Technology, uses brain activity measurements to tailor transcranial magnetic stimulation (TMS). Wave reports that an electroencephalogram (EEG) records electrical activity in the brain, and an AI-assisted algorithm uses those measurements to guide a patient-specific stimulation protocol.
During TMS, a coil placed against the scalp delivers magnetic pulses intended to stimulate brain activity. TMS has previously been FDA-cleared for treatment-resistant depression; the reported PTSD clearance applies to the customized approach described as Magnetic e-Resonance Therapy (MeRT). The source report identifies the regulatory development as FDA clearance but does not give the clearance date or full authorization documents.
The trial figures come from Wave Neuroscience’s account, not a publicly available full study report. The company’s chief medical officer, Erik Won, said participants experienced a 52% reduction in symptoms and that 68% achieved remission. Without the full methods and results, readers cannot determine how many people took part, what comparison group was used, how long outcomes were followed, or whether the results have been independently reviewed.
Potential New Option for PTSD Care
The reported results could matter to people whose PTSD symptoms have not improved enough with existing care. Psychotherapy and medications such as selective serotonin reuptake inhibitors (SSRIs) are established treatment approaches, but the source report notes that some patients continue to have symptoms. A personalized stimulation protocol may add another option if further evidence supports its effectiveness and safety.
The company has described the approach as potentially widening access to treatment, but the reported remission figure alone does not establish how well it will work across different patients or in routine care. The source material cites a U.S. lifetime PTSD estimate of about 6% of Americans and says veterans and women experience higher rates. Those figures indicate the scale of the condition, not the number of people who would be eligible for this specific treatment.
For patients and clinicians, the key distinction is between an encouraging company-reported outcome and a result that can be independently evaluated. Details on adverse events, durability of benefit, and comparisons with standard treatment will shape whether the system changes clinical practice.
PTSD self-help workbook evidence-based coping skills
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Breakthrough Designation to Clearance
PTSD can develop after experiences such as combat, serious accidents, disasters, or violence. Treatment has commonly involved psychotherapy and medications, including sertraline and fluoxetine. A 2020 review of PTSD medication studies cited in the source report found symptom-assessment improvements ranging from 6.8 to 10.1 points; it reported remission rates no higher than 10.9%. Those figures come from a separate body of research and are not a direct comparison with the MeRT trial.
The regulatory timeline included an FDA Breakthrough Device designation in 2024, according to the source report, followed by FDA clearance reported in October 2026. Breakthrough designation is a regulatory program milestone and should not be treated as proof that a device is more effective than existing options. The source says the designation was intended to help advance development and review but does not supply details of the clearance decision.
MeRT builds on TMS by using EEG measurements and an algorithm to individualize stimulation rather than applying a single standardized protocol. Researchers at Texas A&M contributed to the work, including physician-scientist Kenneth S. Ramos, whose research focuses on precision medicine. The approach’s stated rationale is to account for differences in brain activity between patients when selecting stimulation settings.
“In comparison to that study, our FDA trial reported a 52% reduction in symptoms, so more than a four-fold increase in efficacy.”
— Erik Won, Wave Neuroscience chief medical officer
trauma-informed mindfulness workbook for PTSD
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Trial Details Still Await Publication
The most important limitation is that the full trial findings are still being prepared for public release. The source does not provide the participant count, trial duration, study sites, comparison group, eligibility criteria, statistical uncertainty, or the precise measure used to define remission. It also does not report adverse events or explain how long any symptom improvements lasted.
It is not clear from the available material whether the results have been published in a peer-reviewed journal or independently assessed. Nor does the report establish that the reported 52% symptom reduction or 68% remission rate will apply to patients outside the trial. Comparisons with the 2020 medication review are especially limited because the studies may differ in design, participants, follow-up, and outcome measures.
The article’s account describes FDA clearance but does not include the agency’s decision documents, the exact cleared indication, or conditions on use. Those details would help clarify which patients and clinical settings are covered. Until more information is available, the findings are best described as promising company-reported trial outcomes, not proof that the treatment will outperform established care.
noise-canceling headphones for relaxation and sleep
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Full Data Needed to Judge Results
Wave Neuroscience says the full findings are being prepared for public release. Publication of the study methods and results would allow clinicians, researchers, and patients to assess the trial population, outcome measures, safety reporting, and length of follow-up. Details of the FDA clearance would also clarify the authorized use of the system.
Further research and monitoring will be needed to determine whether symptom changes persist and whether outcomes are similar across patient groups. Until those details emerge, decisions about PTSD treatment should be made with a qualified health professional, based on an individual patient’s circumstances and the available evidence.
weighted blanket for calming anxiety
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What treatment was studied?
The study involved Magnetic e-Resonance Therapy (MeRT), which combines EEG measurements of brain activity with an algorithm-guided plan for transcranial magnetic stimulation.
What does the reported 68% remission rate mean?
Wave Neuroscience says 68% of participants achieved remission. The source material does not specify the trial’s definition of remission, participant count, or follow-up period, so the figure cannot yet be fully interpreted.
Has the complete clinical trial been published?
Not according to the source report. It says the full findings are still being prepared for public release; publication and independent assessment are not confirmed in the material provided.
Can the results be compared directly with PTSD medication studies?
No direct comparison is established. The cited medication-review findings and the MeRT trial are from different studies, and the source warns that differences in design and measurement prevent treating them as a head-to-head comparison.
What is known about FDA clearance?
The report says the system received FDA clearance and notes a Breakthrough Device designation in 2024. It does not provide the clearance documents or full details of the authorized indication.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
